This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza
← catalyst calendarNCT07371650 · readout ≤ 134 d
Sponsored by Traws Pharma, Inc. (industry) · TRAW — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
105estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-15 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Influenza
Interventions
- Drug: TRX-100
- Drug: Standard of Care (SOC)
Primary outcomes
what the primary-completion date above is the date OFIncidence of AE/SAE
measured up to Day 28
Incidence of abnormal laboratory tests results
measured Up to Day 28
Incidence of abnormal clinically significant ECG results
measured Up to 28 days
Number of participants with abnormal physical examinations findings
measured Up to 28 days
Permalink · TRAW's whole pipeline · Catalyst calendar · Every registered study · What changed